Rate Notice: 5.9% general rate increase Jan 1, 2026 — Learn More
    UNIS logo
    Boehringer Ingelheim logo featuring a white shield with the companys emblem inside

    Boehringer Ingelheim Pharma

    Global family-owned pharmaceutical company developing innovative medicines for human and animal health, with over 53,000 employees across 130 markets worldwide.

    Company Overview

    Boehringer Ingelheim is one of the world's largest family-owned pharmaceutical companies, founded in 1885 in Ingelheim am Rhein, Germany. The company operates through three core business divisions: Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing, with a strong focus on research-driven innovation in respiratory diseases, metabolism, immunology, oncology, and central nervous system disorders.

    Key Metrics

    2,400

    Import Shipments

    20

    Distribution Centers

    28.9B

    Annual Revenue

    1885

    Founded

    Company Profile

    Key Milestones

    Important company milestones and achievements.

    Markets Served

    Geographic markets and customer segments served.

    Ownership Structure

    Corporate ownership and organizational structure.

    Sales Channels

    Distribution networks and sales approaches.

    Recent Developments

    The company continues to invest heavily in research and development of innovative pharmaceutical therapies, focusing on breakthrough treatments for diseases with unmet medical needs while expanding its biopharmaceutical contract manufacturing capabilities and strengthening its animal health portfolio through strategic partnerships and technological advancement.

    Strategic Expansion

    Significant investment in research and development with expenses reaching 5.047 billion EUR in 2022, representing 20.9% of net sales and employing over 10,600 R&D professionals; expansion of biopharmaceutical contract manufacturing operations with 11.7% growth in net sales; continued strong performance of key products including JARDIANCE family with 48% growth and OFEV with 29.5% growth; ongoing enhancement of production facilities across 20 manufacturing plants in 13 countries to support global pharmaceutical supply chain demands.

    Market Expansion

    Strategic efforts to expand market presence and reach new customer segments.

    Technology Adoption

    Implementation of advanced technologies to improve service delivery and customer experience.

    Business Information

    Boehringer Ingelheim is a research-driven biopharmaceutical company working on breakthrough therapies that transform lives across generations. The company operates major research and development centers in Germany, the United States, and Austria, supplementing its broad portfolio through partnerships with academic institutions, biotech companies, and public research institutions worldwide. With more than 53,000 employees creating value through innovation daily, the company maintains a strong commitment to developing medicines for diseases with no satisfactory treatment options. The company has remained privately held and fully owned by the Boehringer, Liebrecht, and von Baumbach families since its establishment in 1885.

    Headquarters

    Ingelheim am Rhein, Germany

    Founded

    1885

    Stock Symbol

    Private company